Academic Journal
Emerging and Re-Emerging Viral Pathogens in Oncolytic Virotherapy: A Comprehensive Review.
| Τίτλος: | Emerging and Re-Emerging Viral Pathogens in Oncolytic Virotherapy: A Comprehensive Review. |
|---|---|
| Συγγραφείς: | An X; The VIP Department, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang, China., Liu N; Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, China., Liu J; Department of Periodontics, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang, China. |
| Πηγή: | Reviews in medical virology [Rev Med Virol] 2026 Sep; Vol. 36 (5), pp. e70167. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley Country of Publication: England NLM ID: 9112448 Publication Model: Print Cited Medium: Internet ISSN: 1099-1654 (Electronic) Linking ISSN: 10529276 NLM ISO Abbreviation: Rev Med Virol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Chichester, West Sussex, England : Wiley, c1991- |
| Ιατρικοί όροι (MeSH): | Oncolytic Virotherapy*/methods , Oncolytic Viruses*/genetics , Oncolytic Viruses*/physiology , Neoplasms*/therapy , Neoplasms*/virology, SARS-CoV-2/genetics ; SARS-CoV-2/pathogenicity ; Zika Virus/genetics ; Zika Virus/pathogenicity ; West Nile virus/genetics ; Dengue Virus/genetics ; Dengue Virus/pathogenicity ; Humans ; Animals |
| Περίληψη: | Oncolytic virotherapy has recently emerged as a promising immuno-oncological strategy, utilising the natural cytolytic potentials of viral pathogens to selectively target and destroy malignant cells. Although various engineered viruses, such as adenoviruses, vaccinia virus, and herpes simplex virus, are currently in clinical evaluation, emerging and re-emerging viruses with intrinsic oncolytic potential, including Zika virus (ZIKV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Dengue virus (DENV), and West Nile virus (WNV), have also shown promising results. These emerging and re-emerging viral pathogens show specific tumour tropism, immune evasion strategies, and immunogenic cell death mechanisms that could be harnessed for next-generation therapeutic platforms. Nonetheless, concerns related to safety, viral pathogenicity, host immune responses, and the risk of uncontrolled viral dissemination present significant translational challenges. The present review provides a comprehensive overview of novel viral candidates, including ZIKV, SARS-CoV-2, DENV, and WNV, in oncolytic virotherapy, their molecular mechanisms of tumour targeting, and current advancements in genetic engineering aimed at improving therapeutic efficacy and biosafety. Moreover, this review describes clinical perspectives, regulatory considerations, and future directions in integrating emerging virotherapeutic agents into precision oncology. (© 2026 John Wiley & Sons Ltd.) |
| References: | Oncol Rep. 2025 Sep;54(3):. (PMID: 40576111) Biomedicines. 2014 Apr 17;2(2):163-194. (PMID: 28548066) Sci Transl Med. 2018 Jan 31;10(426):. (PMID: 29386359) Gene Ther. 2003 Aug;10(15):1241-7. (PMID: 12858189) Cell Rep. 2017 Jan 10;18(2):324-333. (PMID: 28076778) Front Immunol. 2025 Aug 25;16:1618751. (PMID: 40927720) Mol Ther Methods Clin Dev. 2021 Mar 12;20:350-356. (PMID: 33521163) Nat Rev Drug Discov. 2019 Sep;18(9):689-706. (PMID: 31292532) Cancer Treat Res Commun. 2021;27:100323. (PMID: 33530025) Int J Nanomedicine. 2012;7:985-97. (PMID: 22412299) Cells. 2026 Feb 24;15(5):. (PMID: 41827827) Medicina (Kaunas). 2022 Jan 18;58(2):. (PMID: 35208467) J Transl Med. 2023 Jul 19;21(1):483. (PMID: 37468934) Indian J Med Res. 2012 Oct;136(4):571-84. (PMID: 23168697) Future Virol. 2018 Sep;13(9):671-680. (PMID: 30416535) Ther Adv Med Oncol. 2021 Apr 29;13:17588359211011455. (PMID: 33995596) Oncol Lett. 2024 Feb 22;27(4):169. (PMID: 38455664) J Transl Med. 2023 Apr 21;21(1):273. (PMID: 37085802) Pharmaceutics. 2022 Feb 25;14(3):. (PMID: 35335891) Case Rep Hematol. 2022 Jan 20;2022:2603607. (PMID: 35070460) J Control Release. 2025 Jul 10;383:113822. (PMID: 40348130) Br J Haematol. 2021 Feb;192(3):415. (PMID: 33386647) Biotechnol Bioeng. 2023 Sep;120(9):2601-2621. (PMID: 37126355) Mol Ther Methods Clin Dev. 2020 Jan 15;17:349-358. (PMID: 32071927) PLoS Pathog. 2021 Jan 29;17(1):e1009240. (PMID: 33513191) Cell Biochem Funct. 2010 Jul;28(5):343-51. (PMID: 20535838) Vaccines (Basel). 2023 Sep 01;11(9):. (PMID: 37766125) Front Bioeng Biotechnol. 2022 Aug 09;10:921755. (PMID: 36017347) Annu Rev Pathol. 2021 Jan 24;16:167-198. (PMID: 33264572) Front Cell Infect Microbiol. 2023 Mar 15;13:1142172. (PMID: 37009515) Viruses. 2024 Nov 12;16(11):. (PMID: 39599878) J Infect Dis. 2021 Feb 3;223(2):258-267. (PMID: 32572470) Mol Ther. 2014 Feb;22(2):251-256. (PMID: 24048442) Sci Rep. 2016 Dec 23;6:39775. (PMID: 28008958) Cell Stem Cell. 2020 Feb 6;26(2):187-204.e10. (PMID: 31956038) Mol Ther Oncol. 2025 Dec 09;34(1):201106. (PMID: 41552759) Int J Mol Sci. 2021 Oct 12;22(20):. (PMID: 34681654) Viruses. 2024 Jan 31;16(2):. (PMID: 38399989) J Clin Med. 2023 Jan 31;12(3):. (PMID: 36769745) J Virol. 2015 Sep;89(17):8880-96. (PMID: 26085147) Cells. 2025 Apr 09;14(8):. (PMID: 40277888) Mol Aspects Med. 2025 Aug;104:101371. (PMID: 40424828) Sci Rep. 2017 Nov 30;7(1):16652. (PMID: 29192272) Biomed Pharmacother. 2023 Feb;158:114094. (PMID: 36502755) Front Microbiol. 2019 Nov 20;10:2715. (PMID: 31824472) Front Immunol. 2025 Jan 08;15:1535647. (PMID: 39845957) Clin Cancer Res. 2018 May 1;24(9):2128-2137. (PMID: 29437789) J Infect Dis. 2017 Dec 16;216(suppl_10):S891-S896. (PMID: 29267916) Cell Stem Cell. 2016 May 5;18(5):587-90. (PMID: 26952870) J Egypt Natl Canc Inst. 2025 Sep 29;37(1):62. (PMID: 41016975) Mol Cancer. 2025 Oct 14;24(1):254. (PMID: 41088352) Mol Cancer. 2025 Oct 31;24(1):277. (PMID: 41174733) Mol Ther Oncol. 2025 Oct 16;33(4):201069. (PMID: 41211543) J Immunother Cancer. 2021 Apr;9(4):. (PMID: 33795384) Hum Gene Ther. 2011 Apr;22(4):489-97. (PMID: 21083425) J Exp Med. 2017 Oct 2;214(10):2843-2857. (PMID: 28874392) Cell Stem Cell. 2016 Jul 7;19(1):120-6. (PMID: 27179424) JCI Insight. 2021 Jan 11;6(1):. (PMID: 33232299) J Gastrointest Oncol. 2024 Aug 31;15(4):1933-1938. (PMID: 39279952) DNA Cell Biol. 2023 Jun;42(6):267-273. (PMID: 36350682) Viruses. 2024 Apr 03;16(4):. (PMID: 38675903) Int J Infect Dis. 2016 Mar;44:11-5. (PMID: 26854199) Microbiol Mol Biol Rev. 2017 Feb 8;81(1):. (PMID: 28179396) Int J Mol Sci. 2023 Jan 24;24(3):. (PMID: 36768649) Mol Ther. 2024 Feb 7;32(2):440-456. (PMID: 38213031) Pharmaceuticals (Basel). 2023 Jun 05;16(6):. (PMID: 37375789) Tumour Virus Res. 2025 Dec;20:200333. (PMID: 41314288) Rev Med Virol. 2018 Nov;28(6):e2008. (PMID: 30209859) Hum Gene Ther. 1999 May 20;10(8):1349-58. (PMID: 10365665) Infect Agent Cancer. 2025 Oct 23;20(1):74. (PMID: 41131532) Front Immunol. 2018 Oct 23;9:2460. (PMID: 30405639) J Pathol. 2020 Jul;251(3):228-248. (PMID: 32418199) Cancer Cell Int. 2022 Apr 29;22(1):168. (PMID: 35488303) Cell Death Dis. 2016 Oct 27;7(10):e2440. (PMID: 27787521) Am J Clin Dermatol. 2017 Feb;18(1):1-15. (PMID: 27988837) Future Oncol. 2022 Jul 12;:. (PMID: 35818970) |
| Grant Information: | 2025-MSLH-772 The Natural Science Foundation of Liaoning Province |
| Contributed Indexing: | Keywords: SARS‐CoV‐2; emerging viruses; oncolytic virotherapy; zika virus |
| Entry Date(s): | Date Created: 20260818 Date Completed: 20260818 Latest Revision: 20260820 |
| Update Code: | 20260820 |
| PubMed Central ID: | PMC13482672 |
| DOI: | 10.1002/rmv.70167 |
| PMID: | 42610315 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!